XNCR vs. MNKD, PRTA, MIRM, ABCL, BLTE, GMTX, COLL, DCPH, PIRS, and MGNX
Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include MannKind (MNKD), Prothena (PRTA), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Belite Bio (BLTE), Gemini Therapeutics (GMTX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), Pieris Pharmaceuticals (PIRS), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical preparations" industry.
Xencor (NASDAQ:XNCR) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.
MannKind has a net margin of -6.00% compared to Xencor's net margin of -74.90%. MannKind's return on equity of 0.00% beat Xencor's return on equity.
Xencor has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
In the previous week, Xencor had 1 more articles in the media than MannKind. MarketBeat recorded 1 mentions for Xencor and 0 mentions for MannKind. Xencor's average media sentiment score of 1.76 beat MannKind's score of 0.00 indicating that Xencor is being referred to more favorably in the media.
MannKind has higher revenue and earnings than Xencor. MannKind is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.
MannKind received 81 more outperform votes than Xencor when rated by MarketBeat users. However, 72.85% of users gave Xencor an outperform vote while only 59.83% of users gave MannKind an outperform vote.
Xencor currently has a consensus price target of $36.00, indicating a potential upside of 80.18%. MannKind has a consensus price target of $8.00, indicating a potential upside of 89.13%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Xencor.
49.6% of MannKind shares are held by institutional investors. 5.0% of Xencor shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
MannKind beats Xencor on 11 of the 18 factors compared between the two stocks.
Get Xencor News Delivered to You Automatically
Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
